CureVac Tanks As Potential Covid Vaccine Fails Trial

Investing.com

Thu, Jun 17, 2021, 1:20 AM1 min read

In this article:

By Dhirendra Tripathi

Investing.com -- CureVac (NASDAQ:CVAC) shares dropped 45% in Thursday’s premarket trading after its candidate for COVID-19 vaccine failed to meet its main goal in late stage clinical trials.

Late Wednesday CureVac said preliminary data indicated that its jab was only 47% effective at protecting against coronavirus and added that final analysis of the trial results would be available in the coming weeks.

The HERALD study, conducted by Curevac in conjunction with Bayer (DE:BAYGN), enrolled approximately 40,000 participants in 10 countries in Latin America and Europe.

The company said demonstrating high efficacy in “unprecedented broad diversity of variants” – as many as 13 that were part of the study -- was challenging.

CureVac Tanks As Potential Covid Vaccine Fails Trial

Britain and United States reach truce in Airbus/Boeing trade dispute

Hawkish Fed fuels dollar, leaves stocks and bonds bruised

Berkshire's profit plunges 64% on portfolio holdings as Buffett sells Apple
Berkshire Hathaway's first quarter profits plummeted along with the paper value of its investments, but the company said Saturday that most of the businesses it owns outright performed well. The figures were heavily influenced by a large drop in the paper value of Berkshire’s investments. Buffett encourages investors to pay more attention to the conglomerate’s operating earnings that exclude the investment figures.
Associated Press Finance
The US could give homeowners a $980 billion stimulus at no additional cost, 'Oracle of Wall Street' says
"As early as this summer, a proposed move could begin to unleash almost $1tn into consumers' wallets. By the autumn, it could be on its way to $2tn."
Business Insider
Here's the 1 Stock Warren Buffett Thinks Should Outperform the S&P 500 Without as Much Downside
A big cash pile protects the above-average core operations of this stellar company.
Motley Fool
This Dividend Stock Yields 4.4% and Has 15 Consecutive Years of Dividend Increases. Here's Why It's a Buy Now
This industry-leading company is out of favor and worth buying now.
Motley Fool
A 64-year-old 'peak boomer' worries his savings and Social Security won't be enough to retire: 'My biggest fear is finding myself at 75 standing at the door at Walmart.'
David Kirsch, 64, is hoping to live comfortably in retirement — but he isn't sure his savings and Social Security will cover his living expenses.
Business Insider
‘We Lost Quite a Bit of Money.’ Berkshire Sold Entire Paramount Stake, Buffett Says.
Berkshire Hathaway has sold its entire stake in Paramount Global losing “quite a bit of money,” Berkshire CEO Warren Buffett said at the company’s annual meeting on Saturday. Buffett also shot down speculation that Ted Weschler or Todd Combs, who together run about 10% of Berkshire Hathaway’s equity portfolio, had purchased the Paramount stake, taking responsibility for the investment himself. “It was 100% my decision and we’ve sold it all and we lost quite a bit of money,” said Buffett.
Barrons.com
This 8.3%-Yielding Dividend Stock Has Plenty of Fuel to Continue Producing Prodigious Amounts of Passive Income
MPLX is a well-oiled cash-producing machine.
Motley Fool
Why Warren Buffett's billions in cash at Berkshire Hathaway is a bearish stock market signal
Berkshire Hathaway cut its stake in Apple by about 13% as its cash pile hit a record high in the first quarter. A bearish signal all around?
Yahoo Finance
Intel CEO Pat Gelsinger Picks Up Stock Near 2024 Low
Intel stock continued a 2024 slump in late April after the chip maker provided disappointing guidance. With the shares trading at their lows for this year, CEO Pat Gelsinger bought up Intel stock on the open market. According to forms he filed with the Securities and Exchange Commission, Gelsinger purchased the stock through a family trust that now owns 39,400 shares.
Barrons.com
Markets worry Treasury yields could jump back to levels that sparked chaos last October
The 10-year Treasury rate has creeped up through this year, and is not far from levels that sparked a massive sell-off last October.
Business Insider

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CureVac Tanks As Potential Covid Vaccine Fails Trial

Recommended Stories

Berkshire's profit plunges 64% on portfolio holdings as Buffett sells Apple

The US could give homeowners a $980 billion stimulus at no additional cost, 'Oracle of Wall Street' says

Here's the 1 Stock Warren Buffett Thinks Should Outperform the S&P 500 Without as Much Downside

This Dividend Stock Yields 4.4% and Has 15 Consecutive Years of Dividend Increases. Here's Why It's a Buy Now

A 64-year-old 'peak boomer' worries his savings and Social Security won't be enough to retire: 'My biggest fear is finding myself at 75 standing at the door at Walmart.'

‘We Lost Quite a Bit of Money.’ Berkshire Sold Entire Paramount Stake, Buffett Says.

This 8.3%-Yielding Dividend Stock Has Plenty of Fuel to Continue Producing Prodigious Amounts of Passive Income

Why Warren Buffett's billions in cash at Berkshire Hathaway is a bearish stock market signal

Intel CEO Pat Gelsinger Picks Up Stock Near 2024 Low

Markets worry Treasury yields could jump back to levels that sparked chaos last October